Incannex Healthcare welcomes leading psychedelics experts to board of Clarion Clinics Group
Clinical stage pharmaceutical development company Incannex Healthcare (ASX: IHL) has announced that global psychedelic therapy and science experts Doctor Bill Richards, Dr Andrea Jungaberle and Professor Matthew Johnson have joined the advisory board of its newly-established subsidiary Clarion Clinics Group.
Dr Richards has a multi-decade career at the forefront of psychedelic research, therapy and training and is a mentor and trainer to numerous research groups around the world.
He co-founded the psychedelic research group at US-based Johns Hopkins University and is the director of therapy at Sunstone Therapies in Maryland.
Dr Jungaberle is chief medical officer of Ovid Clinics in Germany and co-founder of the MIND Foundation, which is Europe’s leading psychedelic research and education group.
She has conducted and supervised psychedelic-assisted psychotherapy for hundreds of patients and works within Germany’s largest clinical psilocybin trial as well as on clinical service delivery.
Professor Johnson has been central in the establishment of the Johns Hopkins Centre for Psychedelic & Consciousness Research and his work has contributed to standards in practice within clinical psychedelic science.
He is one of the world’s most published psychedelic scientists and is frequently interviewed by national and international media outlets.
Collaborative venture
Clarion is a collaborative venture between Incannex and Australian psychedelics leaders Dr Paul Liknaitzky, Professor Suresh Sundram and Sean O’Carroll, who are co-founders, key executives and directors of the company.
The group’s first psychedelic-assisted psychotherapy clinic is based in Melbourne and will open its doors to patients later this year, after which the company intends to expand rapidly.
Dr Liknaitzky welcomed the new members of the board.
“Bill, Andrea and Matt are wonderful colleagues and inspiring people,” he said.
“Each of them brings deep experience and hard-won wisdom which will help guide our efforts within the Clarion venture towards supporting our clients to live their best lives.”
Esteemed professionals
Incannex director Peter Widdows said he was pleased to welcome three of the industry’s esteemed professionals to Clarion.
“As Australia is the first country to legalise the use of psychedelic drugs in the treatment of mental illness, the eyes of the world are upon us, and having people of this calibre and experience on board will help us ensure we provide world-leading effective treatments in an ethical and safe way,” he said.